Abstract |
The clinical efficacy of COP-BLAM chemotherapy combined with human recombinant granulocyte colony-stimulating factor ( G-CSF) was evaluated in 104 previously untreated patients with non-Hodgkin's lymphoma (NHL). According to the method of Laurence et al., a modified COP-BLAM regimen was administered every 21 days. G-CSF was added when the granulocyte count fell below 1000 x 10(9)/l. Ninety-eight of 104 (94.2%) patients achieved a complete remission; the 4-year survival rate was 82.4% with a median duration of observation of 26 months. Survival was significantly longer in patients with low serum LDH levels, B-cell type or low CRP or in earlier clinical stages, than in patients with high serum LDH levels, T-cell type of higher CRP levels or in advanced clinical stages. The mean duration of administration of G-CSF was 5.4 days. Twelve patients developed infections during treatment. The adverse effects of G-CSF included interstitial pneumonia, bone pain and fever. Patients administered COP-BLAM combined with G-CSF achieved a high rate of remission and had a low incidence of infection. Nearly all the patients could be treated in 21-day cycles. The results suggest that G-CSF combined with COP-BLAM was effective in treating NHL, because the patients can tolerate a higher dose of the anticancer agents.
|
Authors | N Niitsu, M Umeda |
Journal | European journal of haematology
(Eur J Haematol)
Vol. 55
Issue 2
Pg. 88-92
(Aug 1995)
ISSN: 0902-4441 [Print] England |
PMID | 7543059
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Recombinant Proteins
- Bleomycin
- Granulocyte Colony-Stimulating Factor
- Procarbazine
- Vincristine
- Doxorubicin
- Cyclophosphamide
- Prednisone
|
Topics |
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Bleomycin
(administration & dosage, adverse effects)
- Cyclophosphamide
(administration & dosage, adverse effects)
- Doxorubicin
(administration & dosage, adverse effects)
- Female
- Fever
- Granulocyte Colony-Stimulating Factor
(administration & dosage, adverse effects)
- Humans
- Infections
- Lymphoma, Non-Hodgkin
(drug therapy, pathology)
- Male
- Middle Aged
- Neoplasm Staging
- Neutropenia
- Prednisone
(administration & dosage, adverse effects)
- Procarbazine
(administration & dosage, adverse effects)
- Recombinant Proteins
(administration & dosage)
- Remission Induction
- Vincristine
(administration & dosage, adverse effects)
|